DEINOVE TAKES ON A WHOLE NEW DIMENSION WITH THE ACQUISITION OF MORPHOCHEM’S CLINICAL-STAGE ANTIBIOTIC COMPOUND

April 13, 2018
DEINOBIOTICS/DEINOVE

Montpellier, 13 April 2018 (6:30am CEST) - DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, announces the acquisition, through a contribution-in-kind transaction, of the entire capital3 of the Austrian company Biovertis AG (“BIOVERTIS”), which owns the entire capital of the German company Morphochem AG für kombinatorische Chemie (“MORPHOCHEM”), with the latter developing the clinical-stage antibiotic compound “MCB3837”. Subject to approval by DEINOVE's shareholders' meeting, all shareholders, option and right holders of BIOVERTIS will become shareholders of DEINOVE.

Press Release available here: